GENE EXPRESSION PROFILING IDENTIFIES CHARACTERISTIC TRANSCRIPTIONAL SIGNATURES OF GENOMIC INSTABILITY IRRESPECTIVE OF TP53 IMPAIRMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Johannes Bloehdorn, 214639
CD20 IS A DIRECT REGULATOR OF B-CELL RECEPTOR SIGNALING IN THE MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Gabriela Pavlasova, 214654
ROLE OF MTORC1 IN NORMAL HAEMOPOIESIS AND LEUKAEMOGENESIS
EHA Learning Center, Natasha Malik, 214655
HUMAN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA DEVELOPS HYPOXIA-RELATED CHEMORESISTANCE THROUGH HIF1Α AND MTOR PATHWAY INTERACTIONS
EHA Learning Center, Lucine Fahy, 215238
CLONAL EVOLUTION OF ACUTE LYMPHOBLASTIC LEUKEMIA CELLS FROM DIAGNOSIS TO RELAPSE
EHA Learning Center, shumaila sayyab, 215239
PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AND MLL REARRANGEMENT SHOW A DISTINCTIVE EXPRESSION PATTERN OF HISTONE DEACETYLASES
EHA Learning Center, Nerea Vega-Garcia, 215255
PROTEOLYTIC L-ASPARAGINASE DEGRADATION AS A MECHANISM FOR NON-ANTIBODY-RELATED DRUG INACTIVATION
EHA Learning Center, Justyna Walenciak, 215256
HEMATOPOIETIC FUNCTIONS OF R396Q AND R204X GATA2 MUTANTS SUGGEST DISTINCT MECHANISMS LEADING TO THE GATA2 SYNDROME
EHA Learning Center, Eric DELABESSE, 215272
SYNERGISTIC INHIBITORY EFFECT OF HYDROXYUREA AND DECITABINE ON THE PROLIFERATION OF AML CELLS
EHA Learning Center, Konstantin Byrgazov, 215273
TARGETED COMBINATION THERAPY AGAINST ONCOGENIC PI3K/AKT/MTOR AND NFKB SIGNALLING PATHWAYS USING ACUTE MYELOID LEUKEMIA AS A CANCER MODEL
EHA Learning Center, Montserrat Estruch, 215289
IDENTIFICATION OF GENE COPY NUMBER ABERRATIONS AS PROGNOSTIC MARKERS OF SURVIVAL IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS BY EXOME SEQUENCING OF LEUKEMIA DNA IN THE MAYO CLINIC AML EPIDEMIOLOGY COHORT
EHA Learning Center, Yan Asmann, 215290
CONTINUING ENASIDENIB TREATMENT FOR PATIENTS WITH MUTANT-IDH2 RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) WITH STABLE DISEASE MAY RESULT IN IMPROVED RESPONSES AND SURVIVAL OVER TIME
EHA Learning Center, Eytan M. Stein, 215305
PH II TRIAL WITH SELECTIVE ORAL AXL INHIBITOR BEMCENTINIB (BGB324) IN RELAPSED/REFRACTORY AML AND MDS: IDENTIFICATION OF PREDICTIVE AND PHARMACODYNAMIC BIOMARKER CANDIDATES ASSOCIATED WITH PT BENEFIT
EHA Learning Center, Julia Schoelermann, 215306
PHASE 1/1B STUDY OF PEVONEDISTAT (PEV) AS A SINGLE AGENT OR COMBINED WITH AZACITIDINE (AZA) IN EAST ASIAN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
EHA Learning Center, SHANG-JU WU, 215321
ANALYSIS OF PHASE I AND PILOT PHASE II DATA REVEAL 2,000 MG/M2 AS THE OPTIMAL DOSE OF CPI-613 IN COMBINATION WITH CYTARABINE AND MITOXANTRONE FOR ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY AML
EHA Learning Center, Timothy Pardee, 215322
CC-122-DLBCL-001: PHASE IB STUDY OF CC-122 PLUS RITUXIMAB IN PATIENTS WITH CHEMO-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Vincent Ribrag, 215337
EXTRACELLULAR CIRCULATING DNA IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: BIOLOGICAL CORRELATES AND PROGNOSTIC IMPACT
EHA Learning Center, Dino Dujmovic, 215338
GLOBAL LONGITUDINAL STRAIN (2D-GLS) IN LYMPHOMA PATIENTS TREATED WITH CHEMOTHERAPY +/- MEDIASTINAL RADIOTHERAPY: EARLY SUBCLINICAL CARDIOTOXICITY IN THE CARDIOCARE PROSPECTIVE OBSERVATIONAL STUDY.
EHA Learning Center, Barbara Botto, 215353
CLINICAL FEATURES, TREATMENT AND PROGNOSTIC FACTORS FOR EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE, IN THE SPANISH POPULATION. A STUDY FROM THE SPANISH GROUP GELTAMO.
EHA Learning Center, EVA GONZALEZ BARCA, 215354
CONGENITAL FXIII DEFICIENCY IN PAKISTAN
EHA Learning Center, Munira Borhany, 215369
DISSEMINATED INTRAVASCULAR COAGULATION SCORING IN CHILDREN WITH ACUTE LEUKEMIA: IS THERE A SIMPLER AND ECONOMICAL ALTERNATIVE?
EHA Learning Center, Yasmine El Chazli, 215370
HIGHER RATE OF DYSMORPHIC FEATURES IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215385
OPTIMIZING MRD RESPONSE ASSESSMENT USING HIGH-SENSITIVITY PERIPHERAL BLOOD MONITORING DURING TREATMENT WITH IBRUTINIB COMBINED WITH OBINUTUZUMAB OR VENETOCLAX IN CLL .
EHA Learning Center, Andy C. Rawstron, 215386
SINGLE CELL ABNORMALITIES ON CLASSIC G-BANDING ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A NEW DIAGNOSTIC AND BIOLOGICAL CHALLENGE?
EHA Learning Center, Anastasia Athanasiadou, 215402
HIGHER RESPONSIVENESS OF CLL CELLS TO B-CELL RECEPTOR STIMULATION IS ASSOCIATED WITH REDUCED EXPRESSION OF INHIBITORY MOLECULES OF THE NF-ΚB PATHWAY
EHA Learning Center, Ruud Meijers, 215403
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN RELATION TO RESPONSE TO FIRSTLINE THERAPY AND SUBSEQUENT TREATMENTS – A METAANALYSIS OF HRQOL MEASURED IN PHASE III TRIALS OF THE GERMAN CLL STUDY GROUP
EHA Learning Center, Nadine Kutsch, 215418
T-LARGE GRANULAR LYMPHOCYTIC (T-LGL) LEUKEMIA: A LONG-TERM STUDY ON 51 PATIENTS-COULD WE CONFINE THE USE OF THE TERM “LEUKEMIA”?
EHA Learning Center, Xanthi Yiakoumis, 215419
TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
EHA Learning Center, Sukjoong Oh, 215433
TWO YEARS OF THERAPY WITH MATINIB GENERICS IN CHRONIC MYELOID LEUKEMIA; A REPORT FROM THE POLISH ADULT LEUKEMIA GROUP (PALG) IMATINIB GENERICS REGISTRY
EHA Learning Center, Tomasz , 215434
MAINTENANCE THERAPY WITH DASATINIB ADMINISTRATED EVERY OTHER DAY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Clemence Loiseau, 215435
PREVALENCE AND PREDICTORS OF LIVER FIBROSIS EVALUATED BY VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY (FIBROSCAN®) IN ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASE
EHA Learning Center, Maria Domenica Cappellini, 215450
PREVALENCE AND CLINICAL SIGNIFICANCE OF SMALL PNH CLONES IN PATIENTS WITH PRIMARY AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Bruno Fattizzo, 215451
COMBINATION TREATMENT OF RITUXIMAB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOR WARM AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Caroline Piatek, 215452
THE COMBINATION OF CD19/BCMA-DIRECTED CART CELLS INDUCED THERAPEUTIC RESPONSE AND REVERSIBLE COMPARTMENTAL CYTOKINE RELEASE SYNDROME CONFINED TO CEREBRAL REGION IN A PATIENT WITH CNS MULTIPLE MYELOMA
EHA Learning Center, Caixia Li, 215466
INITIAL EXPERIENCE IN US COMMERCIAL MANUFACTURING OF TISAGENLECLEUCEL, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR PEDIATRIC RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Brian Majors, 215467
ALLOGENEIC NK CELLS AND THEIR USE IN CLINICAL TRIALS
EHA Learning Center, Ludovit Bielik, 215468
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III OR IV HODGKIN LYMPHOMA: IMPACT OF CYCLE 2 PET RESULT ON MODIFIED PROGRESSION-FREE SURVIVAL
EHA Learning Center, Robert Chen, 215482
BENDAMUSTINE IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AFTER FAILURE OR SUBOPTIMAL RESPONSES TO NIVOLUMAB THERAPY.
EHA Learning Center, Kirill Lepik, 215483
NIVOLUMAB RESTORES SENSITIVITY TO CHEMOTHERAPY IN CHEMOREFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS
EHA Learning Center, Carmelo Carlo-Stella, 215484
IBRUTINIB MONOTHERAPY IN SYMPTOMATIC, TREATMENT-NAIVE PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA.
EHA Learning Center, Steven Treon, 215498
CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA (OAL): LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL STUDY.
EHA Learning Center, Ritsuko Nakai, 215499
CD5-NEGATIVE MANTLE CELL LYMPHOMA: A DIAGNOSTIC CHALLENGE IN LEUKEMIC NON-NODAL CASES EXCLUSIVELY DIAGNOSED IN PERIPHERAL BLOOD
EHA Learning Center, Sara Montesdeoca Romero, 215500
Clinical and microbiological profile of bloodstream infections in patients with hematological malignancies and febrile neutropenia (PS 1210).
EHA Learning Center, Haydee Bernard, 215515
VACCINATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS – GUIDELINE OF THE INFECTIOUS DISEASES WORKING PARTY (AGIHO) OF THE GERMAN SOCIETY FOR HEMATOLOGY AND MEDICAL ONCOLOGY (DGHO)
EHA Learning Center, Sibylle Mellinghoff, 215517
CHARACTERISTICS OF HEMATOLOGICAL PATIENTS WITH BLOOD CULTURES PROVEN SEPSIS – EXPERIENCE OF ONE CENTER
EHA Learning Center, Karla Jakobac, 215518
PANCREATIC IRON LOADING IN EMOGLOBINOPATHIES.
EHA Learning Center, Alessia Pepe, 215532
CHR AND %HYPO: BETTER METHODS FOR ASSESSING FUNCTIONAL IRON DEFICIENCY IN CHRONIC KIDNEY DISEASE?
EHA Learning Center, Laura Smith, 215533
GROWING IMPORTANCE OF FLOW CYTOMETRY (FCM) IN THE DIAGNOSTICS OF MYELODYSPLASTIC SYNDROMES: SENSITIVITY AND SPECIFICITY OF THE UP-TO-DATE SCORING SYSTEMS UNDER SPECIAL CONSIDERATION OF THE NEW IFSCORE
EHA Learning Center, Uta OELSCHLAEGEL, 215534
AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DURVALUMAB IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AFTER TREATMENT WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Guillermo Garcia-Manero, 215548
SINGLE AGENT TALACOTUZUMAB IN ELDERLY HIGH-RISK MDS OR AML PATIENTS FAILING HYPOMETHYLATING AGENTS – RESULTS OF THE SAMBA STUDY BY THE EMSCO NETWORK
EHA Learning Center, Uwe Platzbecker, 215549
HYPOMETHYLATING AGENTS ASSOCIATED INFECTIONS - SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
EHA Learning Center, Liat shargian-alon, 215550
BI-ALLELIC LOSS OF FAM46C BY CRISPR/CAS9 SYSTEM ENHANCES MYELOMA CELL GROWTH
EHA Learning Center, KANASUGI JO, 215565
MOLECULAR SEGMENTATION OF MULTIPLE MYELOMA BY INTEGRATIVE MULTI-OMICS ANALYSIS
EHA Learning Center, Maria Ortiz Estevez, 215566
SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA
EHA Learning Center, Muntasir Majumder, 215567
MULTIPLE MYELOMA: SINGLE PLARFORM ABSOLUTE COUNT OF CIRCULATING PLASMA CELLS AT DIAGNOSIS CORRELATE WITH POOR PROGNOSIS PARAMETERS.
EHA Learning Center, Vittorio Emanuele Muccio, 215581
MULTIPLE MYELOMA PATHOGENESIS: THE ROLE OF JUNB IN BONE MARROW ANGIOGENESIS
EHA Learning Center, Stefano Malvestiti, 215582
TARGETED LIPOSOMAL MULTI-DRUG DELIVERY TO TUMOR-ASSOCIATED ENDOTHELIUM AS A NOVEL STRATEGY TO REVERSE MICROENVIRONMENT-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA
EHA Learning Center, Cinzia Federico, 215583
WEEKLY CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE 1B STUDY
EHA Learning Center, Noa Biran, 215597
EXTENDED 5-Y FOLLOW-UP OF PHASE 3 ELOQUENT-2 STUDY: ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Katja C Weisel, 215598
LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS.
EHA Learning Center, Francesca Gay, 215599
REAL-WORLD OUTCOMES IN TRANSPLANT INELIGIBLE NDMM PATIENTS: RESULTS FROM A LARGE UK COHORT
EHA Learning Center, FAOUZI DJEBBARI, 215613
BONE MARROW PLASMA CELL INFILTRATION IN LIGHT-CHAIN AMYLOIDOSIS: IMPACT ON ORGAN INVOLVEMENT AND OUTCOME
EHA Learning Center, Luis Gerardo Rodríguez-Lobato, 215614
TREATMENT OF IGM-ASSOCIATED SYSTEMIC AL AMYLOIDOSIS WITH RITUXIMAB-BENDAMUSTINE
EHA Learning Center, Richa Manwani, 215615
A PHASE 1B STUDY USING THE COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASOME IN MULTIPLE MYELOMA PATIENTS PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS
EHA Learning Center, Cristina Gasparetto, 215629
A REAL WORLD RETROSPECTIVE ANALYSIS OF EXTRAMEDULLARY DISEASE FROM BALKAN MYELOMA STUDY GROUP AND BARCELONA UNIVERSITY: CLINICAL FEATURES AND OUTCOME
EHA Learning Center, Meral Beksac, 215630
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN AL AMYLOIDOSIS: SURVIVAL IMPROVEMENT IN DIFFERENT RISK CATEGORIES IN A SINGLE CENTER EXPERIENCE

EHA Learning Center, Angelo Belotti, 215631
IN VIVO INHIBITION OF JAKS IN MYELOFIBROSIS IMPROVES MONOCYTES DIFFERENTIATION AND REACTIVATES PRO-INFLAMMATORY RESPONSE IN INFECTION-STIMULATED MONOCYTES
EHA Learning Center, Lucia Catani, 215645
POLO-LIKE KINASE-1, AURORA KINASE A AND WEE1: NEW THERAPEUTIC TARGETS IN SYSTEMIC MASTOCYTOSIS
EHA Learning Center, Manuela Mancini, 215646
NLR AS SURROGATE OF MYELOID IMMUNE SUPPRESSION CAN PREDICT EARLY SPLENIC RESPONSE TO RUXOLITINIB IN MYELOFIBROSIS
EHA Learning Center, Alfio Bonanno, 215647
FAMILIAL MYELOPROLIFERATIVE NEOPLASMS: A SINGLE-INSTITUTION ANALYSIS OF 22 FAMILIES
EHA Learning Center, Margherita Maffioli, 215661
THROMBOEMBOLIC EVENTS AFTER DIAGNOSIS OF POLYCYTHAEMIA VERA IN A SINGLE CENTER POPULATION
EHA Learning Center, Natalia Curto-Garcia, 215662
MIPSS70 AND TRANSFUSION DEPENDENCE PREDICT SURVIVAL IN MYELOFIBROSIS PATIENTS TREATED WITH JAK1/2 INHIBITOR THERAPY
EHA Learning Center, Caroline Mcnamara, 215663
CLINICAL, PATHOLOGICAL AND MOLECULAR STUDY OF 46 PATIENTS WITH A DIAGNOSIS OF CD5-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA.
EHA Learning Center, Vincent Allain, 215678
THE NOVEL TUMOR SUPPRESSOR SAMHD1 IS FREQUENTLY DOWNREGULATED AND CORRELATES WITH GERMINAL CENTER PHENOTYPE IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Learning Center, Ioanna Xagoraris, 215679
DUAL TARGETING OF BRD4 BY AZD5153 AND BCL2 BY AZD4320 FOR HIGH-RISK B-CELL LYMPHOMAS CONCOMITANTLY OVEREXPRESSING C-MYC AND BCL2
EHA Learning Center, Junya Kuroda, 215680
FEATURES OF PRN1008, A BRUTON’S TYROSINE KINASE INHIBITOR, IN CLINICAL DEVELOPMENT FOR IMMUNE THROMBOCYTOPENIC PURPURA
EHA Learning Center, Steven Gourlay, 215695
ATRA CORRECTS IMPAIRED MACROPHAGE FUNCTION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA THROUGH A20/NLRP3 SIGNALING PATHWAY
EHA Learning Center, Yun He, 215696
RH-TPO RESTORES MEGAKARYOCYTES AND BONE MARROW NICHE COMPONENTS IN THE TREATMENT OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CIRRHOSIS ASSOCIATED WITH HEPATITIS B
EHA Learning Center, Wan-Yi Zhai, 215697
STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL PATIENTS DURING THE FIRST YEAR OF IBRUTINIB TREATMENT
EHA Learning Center, Bozena Sokolowska, 215712
VALIDATION OF THE PLASMIC SCORE FOR THROMBOTIC MICROANGIOPATIES IN A SINGLE UNVERSITY HOSPITAL
EHA Learning Center, Maria del Carmen Ballester Ruiz, 215713
OCCURRENCE AND MANAGEMENT OF HEPATOBILIARY ADVERSE EVENTS (AES) IN ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING LONG-TERM TREATMENT WITH ELTROMBOPAG: RESULTS FROM THE EXTEND STUDY
EHA Learning Center, Abderrahim Khelif, 215714
CLARITHROMYCIN ADDED TO THE VCD REGIMEN CAUSES REDUCED HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Lene Kongsgaard Nielsen, 215728
RELINF PROJECT: PROSPECTIVE EPIDEMIOLOGICAL REGISTRY OF LYMPHOID NEOPLASMS IN SPAIN, ON BEHALF OF GELTAMO GROUP
EHA Learning Center, M Bastos Oreiro, 215729
CORRELATION BETWEEN HEMOLYSIS AND HYPERCOAGULABILITY MARKERS AND EFFECTS OF HYDROXYUREA THERAPY IN SICKLE CELL PATIENTS
EHA Learning Center, Maria de Fátima Sonati, 215745
INFLUENCE OF BCL11A POLYMORPHYSMS ON FETAL HEMOGLOBIN LEVELS AND HAEMOLYSIS MARKERS IN SICKLE CELL ANEMIA PEDIATRIC PATIENTS NOT RECEIVING HYDROXYUREA
EHA Learning Center, Dalila Luciola ZANETTE, 215746
ROLE OF IFN-GAMMA IN IMMUNE-MEDIATED GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Pietro Merli, 215761
EFFECTS OF POST-AUTO-HSCT MRI BONE MARROW LESIONS ON PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MM
EHA Learning Center, Maxim Solovev, 215762
SECOND TRANSPLANT FOR PRIMARY GRAFT FAILURE , FOLLOWING HAPLOIDENTICAL GRAFTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
EHA Learning Center, SABRINA GIAMMARCO, 215777
SUBPOPULATIONS OF MONOCYTES AND B REGULATORY CELLS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Drazen Pulanic, 215778
THE RELATIONSHIP BETWEEN SELECTIVE PRE-TRANSPLANTATION IMMUNE PARAMETERS AND EARLY INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES UNDERGOING ASCT – PRELIMINARY REPORT
EHA Learning Center, Agnieszka Szymczyk, 215793
SELECTIVE HSC-ABLATION USING ANTI-CD117 ANTIBODY DRUG CONJUGATE ENABLES SAFE AND EFFECTIVE AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Agnieszka Czechowicz, 215794
ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA AND ACUTE PANCREATITIS: VARIABLE AND RECIPROCAL PATHOPHYSIOLOGIC RELATIONSHIPS
EHA Learning Center, Qian (Janie) Qin, 215810
EVALUATION OF LUPUS ANTICOAGULANT TESTING: A THREE YEAR EXPERIENCE
EHA Learning Center, Isabel Izquierdo García, 215811
MASSIVE TRANSFUSION PROTOCOLS - FRIEND OR FOE ?
EHA Learning Center, Moon Ley Tung, 215826
PLATELET-DERIVED MICROPARTICLES; THE EXPRESSION PROPERTIES AND POTENSIAL AS A SUBSTITUTE FOR PLATELETS
EHA Learning Center, Shima Azadpour, 215827
MIR-497~195 CLUSTER IS ASSOCIATED WITH FAVORABLE OUTCOME AND HAS A TUMOR SUPPRESSIVE FUNCTION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Elena Boldrin, 215890
MICRORNA-142 IS AN ESSENTIAL REGULATOR OF B CELL DEVELOPMENT AND MALIGNANT TRANSFORMATION
EHA Learning Center, Wei-Le Wang, 215891
INTESTINAL COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE PATHOGENS IN HEMATOLOGICAL PATIENTS: REAPPRAISAL OF SELECTIVE ORAL DECONTAMINATION
EHA Learning Center, Igor Stoma, 215906
EMERGING MICROBIAL RESISTANCE IN FEBRILE NEUTROPENIA- IS IT HIGH TIME TO EVALUATE QUALITY CONTROL MEASURES?
EHA Learning Center, Nida Anwar, 215907
INCREASED PLATELET RESPONSE TO ENDOGENOUS AGONISTS, IN PRE-DIABETIC C57BL/6 MICE
EHA Learning Center, Zibusiso Mkandla, 215922

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings